Review for 10.1186/s12876-020-01584-6 (2021)

Reviewer’s report
Title: 
Differential gene expression analysis of dasatinib-induced colitis in a
patient with chronic myeloid leukemia followed for 3 years: a case report
Version: 
0 
Date: 
25 Sep 2020
Reviewer's report:
Dr. Oshima and the colleagues reported a case of dasatinib-induced colitis and
they also performed transcriptome analyses using colonic mucosa specimens.
Advances in TKIs have made it easier to control CML and more and more
patients are taking dasatinib for long periods. Therefore, it is important to
understand adverse events of dasatinib. It is known that dasatinib causes the
increase of large granular lymphocytes, which is associated with pleural
effusion, one of the most important AEs of dasatinib. Colitis has also been
recognized one of the AEs concerning lymphocytes induced by dasatinib. In this
case report, I think it would be better to focus on a detailed analysis of the
increased lymphocytes and the genes with apparently increased expression in a
patient with dasatinib-induced colitis.
1. Details of increased peripheral lymphocytes, such as flow cytometry analysis,
morphological features (ex. percentage of LGL), transcriptome analysis (if
possible), should be shown. Because adverse events, such as pleural effusion and
colitis, have been suggested to be associated with lymphocytes increased by
dasatinib, it is necessary to provide details. 
2. According to Figure 3A and supplementary table, about two thirds of genes
appear to be on the line of 2-fold change (or 0.5-fold). How are the GO results
when genes are limited to those with apparently increased (ex. 3-fold or higher)
or decreased expression, eliminating these borderline genes?
3. The description in the second paragraph of Background section (P4) should be
reconsidered because most patients with dasatinib-induced colitis are
asymptomatic.
4. Are the endoscopic findings, pathological findings, and transcriptome analysis
presented in Figures 1 and 3 using the specimens from endoscopy at the time of
diagnosis (CS1)?
5. Check a grammatical error of the title ("in a patient" instead of "in patient").
Publons Reviewer Recognition
. Springer Nature can send verification of this
review directly to Publons (a subsidiary of Clarivate Analytics). If you would
like to take advantage of this service, please click on the “Yes” option below.
Your name, email address, title of the reviewed manuscript, name of the journal,
and date of your review submission (the “Review Data”) will then be transmitted
to Publons upon publication of the manuscript. If you have already registered at
Publons, they will notify you of the receipt of this review and update your profile
as per your settings and their policy. If you are not registered with Publons, you
will receive an email from them asking you to register in order for them to be
able to recognize your review on your new profile page. Publons may use the
Review Data to generate derivative metadata for the benefit of Publons and you
as a reviewer, carefully considering the sensitivity of such information. For
example, Publons may verify your record as a reviewer by updating your profile
published on its webservice if you have registered for such service or help
editors to identify candidate reviewers. Please find the details of processing in
Publons’ privacy policy 
https://publons.com/about/terms
No
Declaration of competing interests
Please complete a declaration of competing interests, considering the following
questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
'I declare that I have no competing interests.
Reviewer Publication Consent.
 I agree for my report to be made available
under an Open Access Creative Commons CC-BY License (
http://creativecommons.org/licenses/by/4.0
) if this manuscript is accepted for
publication. Any comments that I do not wish to be included in the published
report have been included as confidential comments to the editor, which will not
be published.
If you are not happy for us to publish this report, please contact the editorial
office before completing the review.
If you wish, you can include your name in your published report. Please note
you must decide whether to include your name at the start of the process and
confirm this decision whenever prompted. If you change your decision later, we
will not be able to publish your name.
I agree to the terms of the CC-BY 4.0 license; please 
do not
 publish my name
with my report. (default)
Is the study design appropriate to answer the research question (including the use
of appropriate controls), and are the conclusions supported by the evidence
presented?
Yes
Are the methods sufficiently described to allow the study to be repeated?
Yes
Is the use of statistics and treatment of uncertainties appropriate?
Yes
Is the presentation of the work clear?
Yes
Are the images in this manuscript (including electrophoretic gels and blots) free
from apparent manipulation?
Yes